Genentech reports positive interim data from Phase III trial of emicizumab for haemophilia A
Roche's biotechnology subsidiary Genentech has reported positive interim results from the Phase III HAVEN 2 clinical trial of emicizumab for the treatment of children with haemophilia A and inhibitors to factor VIII.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Child Development | Children | Clinical Trials | Haemophilia | Hemophilia | Pharmaceuticals